Tag: GlaxoSmithKline

Kenya to Use World’s First Malaria Vaccine

vaccine
Kenya has become the third African country to introduce the world’s first malaria vaccine into the country, in a phased pilot programme. The World Health Organization (WHO) has announced that Kenya...

GSK Announced Positive Results of ZEJULA Phase 3 Study

GlaxoSmithKline plc announced positive results from PRIMA, the Phase 3 randomized, double-blind, placebo-controlled, study of ZEJULA (niraparib) as a maintenance therapy in patients with first-line ov...

ViiV Healthcare Launch Study for First-Ever Long-Acting Injectable Therapy for HIV

viiv healthcare
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced the start of the CUSTOMIZE trial (Cabotegravir plus Ril...

Partnership for New Parkinson’s Disease Treatment

The University of Dundee‘s Drug Discovery Unit (DDU) has announced a multi-million-pound partnership with Korean-based Bukwang Pharmaceutical Company in a bid to develop a new drug treatment for Parki...

EC Granted Marketing Authorisation for HIV-1 Treatment by ViiV Healthcare

hiv
ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, announced that the European Commission has granted Marketi...

FDA Accepted GSK’s Application for ZEJULA with Priority Review

fda
GlaxoSmithKline plc announced that TESARO, an oncology-focused business acquired by GSK, submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for ZEJULA ...

GSK and Novartis Promote False Claims about Products Efficacy

The Federal Court of Australia has found that the subsidiaries of pharmaceutical companies GlaxoSmithKline (GSK) and Swiss drug manufacturer Novartis breached Australian Consumer Law by promoting fals...

Bharat Biotech Acquires Manufacturer of Rabies Vaccines from GSK

Bharat Biotech announces the forthcoming acquisition of Chiron Behring Vaccines Pvt Ltd, located in Ankleshwar, Gujarat from GlaxoSmithKline Asia. Bharat Biotech will acquire 100% equity stake in Chir...

GSK and Merck to Develop Cancer Treatment under €3.7bn Deal

GlaxoSmithKline (GSK) and Merck will develop and commercialize novel immunotherapy to treat multiple cancers, under €3.7bn worth deal. The M7824 is an investigational bifunctional fusion protein im...

FDA Approved Mylan’s Asthma Generic

The U.S. Food and Drug Administration (FDA) approved Mylan NV’s generic version of GlaxoSmithKline-developed blockbuster asthma treatment Advair, driving shares of Mylan 7 percent higher on Wednesday....

GSK and Sanofi Take Part in FinnGen

GlaxoSmithKline and Sanofi have joined academic groups and other pharma companies to take part in Finland’s large scale genomics project, based on data from 500,000 biobank volunteers. FinnGen aims...

GSK Completed Tesaro Acquisition

British drugmaker GlaxoSmithKline (GSK) has completed the acquisition of the US-based oncology-focused biopharmaceutical firm Tesaro for $5.1bn (£4bn). Tesaro acquisition will enable GSK to strengt...

Big Pharma Companies to Raise Drug Prices in January

Novartis AG and Bayer AG are among nearly 30 drugmakers that have taken steps to raise the U.S. prices of their medicines in January, ending a self-declared halt to increases made by a pharma industry...

New-Made Largest Over-the-Counter Products Firm in the World

GlaxoSmithKline has announced its second major deal this month, signing an agreement with Pfizer to combine its consumer health business and form a joint venture with combined annual sales of $12.7 bi...

Manufacturing of Tivicay® in Moscow will be launched no later than May 2019

gsk-servier
GSK and Servier signed an agreement to launch the manufacturing of innovative HIV drug Tivicay® (INN: dolutegravir) in the production facility of Servier Rus pharmaceutical plant in Moscow.

GSK received approval for Shingrix vaccine in Europe and Japan

gsk
GlaxoSmithKline announced that the European Commission has approved Shingrix for the prevention of shingles and post-herpetic neuralgia. The Japanese Ministry of Health, Labour and Welfare has also approved Shingrix.